Cytokinetics Announces Preclinical Data for CK-3773274 Presented at the Biophysical Society 64th Annual Meeting
February 20, 2020 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 20, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that preclinical data related to CK-3773274 (CK-274) were presented at the...
Cytokinetics to Announce Fourth Quarter Results on March 3, 2020
February 18, 2020 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Feb. 18, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on March 3, 2020 at...
Cytokinetics Announces Publication Relating to Design of GALACTIC-HF, a Phase 3 Clinical Trial of Omecamtiv Mecarbil in Patients With Heart Failure
February 06, 2020 04:30 ET
|
Cytokinetics, Incorporated
Second Interim Analysis in GALACTIC-HF Expected to Occur in Q1 2020 Topline Results Expected in Q4 2020 SOUTH SAN FRANCISCO, Calif., Feb. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated...
Cytokinetics Announces Recipients of Second Annual Communications Fellowship Grants
January 22, 2020 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 22, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced the recipients of its Communications Fellowship Grant program, an annual grant...
Cytokinetics Announces Vision 2025 and Outlines 2020 Corporate Milestones
January 13, 2020 07:30 ET
|
Cytokinetics, Incorporated
Top-line Results from GALACTIC-HF Now Expected in Q4 2020; Commercial Readiness Underway REDWOOD-HCM Initiated; Second Cardiac Myosin Inhibitor Planned to Enter Clinic in 1H 2020 SOUTH SAN...
Cytokinetics Announces Start of Redwood-HCM, a Phase 2 Clinical Trial of CK-3773274
January 06, 2020 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Jan. 06, 2020 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that REDWOOD-HCM (Randomized Evaluation of Dosing With CK-274 in Obstructive...
Cytokinetics Granted Orphan Drug Designation for Reldesemtiv for the Treatment of Amyotrophic Lateral Sclerosis
December 18, 2019 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 18, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug...
Cytokinetics Announces New Results Presented at the International Symposium on ALS/MND
December 05, 2019 07:30 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that new results were presented at the 30th International Symposium on...
Cytokinetics to Participate in the Piper Jaffray Healthcare Conference
November 27, 2019 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 27, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Fady I. Malik, M.D., Ph.D., Executive Vice President, Research &...
Cytokinetics Announces Five Presentations at the International Symposium on ALS/MND
November 26, 2019 16:00 ET
|
Cytokinetics, Incorporated
SOUTH SAN FRANCISCO, Calif., Nov. 26, 2019 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced five poster presentations at the 30th International Symposium on ALS/MND in...